NeuroPace, Inc. (NASDAQ:NPCE), a medical device company specializing in neurological disorders with a market capitalization of $439 million, has been making significant strides in the epilepsy ...

Sees FY25 operating expenses $92M-$95M. Management also outlined its long-range plan of becoming the recognized ...

Responsive neurostimulation has also shown promising results, particularly in patients with idiopathic generalized epilepsy (IGE). A case series reported significant reductions in seizure ...

NeuroPace provided initial financial guidance targets for 2025: Revenue of $92 million – $96 million, representing growth of 15.5% – 20.5% versus the midpoint of the expected 2024 revenue range of $79 ...

1 Department of Biomedical Sciences, Ontario Veterinary College, University of Guelph, Guelph, ON, Canada 2 Department of Clinical Studies, Ontario Veterinary College, University of Guelph, Guelph, ON ...

The study is scheduled to commence early this year and will be followed by a subsequent proof of concept efficacy study in dogs with epilepsy. The potential new idiopathic epilepsy therapy has ...

and primary generalized tonic-clonic seizures in adults with idiopathic generalized epilepsy." The said drug is a generic therapeutic equivalent of the Reference Listed Drug (RLD) from HQ Specialty ...

PURPOSE To determine the characteristics that permit diagnosis of the type of epilepsy beginning in the 1st year of life, and to determine from what age such characteristics are recognisable. PATIENTS ...

Understanding whether a dog is genetically inclined to have seizures can help owners take preventative measures and seek early diagnosis. Idiopathic epilepsy is the most common cause of seizures ...

Canine epilepsy, particularly idiopathic epilepsy (IE), is a prevalent neurological condition affecting dogs. Managing this disorder involves not only controlling seizures but also addressing ...

Three-year targets of 20% revenue CAGR and achievement of cash flow breakeven - MOUNTAIN VIEW, Calif., Jan. 28, 2025 (GLOBE NEWSWIRE) -- NeuroPace, Inc. (Nasdaq: NPCE), a medical device company ...